Atorvastatin API Market Research Report - Forecast till 2027

Atorvastatin API Market: Information by Application (Hypercholesterolemia, Hypertriglyceridemia, Dyslipidemia and others) and Region (North America, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/HC/6413-CR | May 2019 | Region: Global | 85 Pages         

1 Executive Summary

1.1 Market Attractiveness Analysis 14

1.1.1 Global Atorvastatin API Market, By Application 15

1.1.2 Global Atorvastatin API Market, By Region 16

2 Market Introduction

2.1 Definition 17

2.2 Scope of the Study 17

2.3 Market Structure 17

3 Research Methodology

3.1 Research Process 18

3.2 Primary Research 19

3.3 Secondary Research 20

3.4 Market Size Estimation 20

3.5 Forecast Model 21

3.6 List of Assumptions 22

4 Market Dynamics

4.1 Introduction 23

4.2 Drivers 24

4.2.1 High Adoption of Atorvastatin in the Treatment of Cardiovascular Diseases 24

4.2.2 Drivers Impact Analysis 24

4.3 Restraints 25

4.3.1 Adverse Health Effects Associated with Atorvastatin 25

4.3.2 Restraints Impact Analysis 25

4.4 Opportunities 26

4.4.1 Growing Prevalence of Dyslipidemia in China 26

5 Market Factor Analysis

5.1 Value Chain Analysis 27

5.1.1 Research and Development 27

5.1.2 Manufacturing 27

5.1.3 Distribution & Sale 28

5.1.4 Post-Sale Monitoring 28

5.2 Porter’s Five Forces Model 28

5.2.1 Threat of New Entrants 29

5.2.2 Intensity of Rivalry 29

5.2.3 Threat of Substitutes 29

5.2.4 Bargaining Power of Suppliers 29

5.2.5 Bargaining Power of Buyers 29

5.3 Regulatory Scenario 30

5.4 Pipeline Analysis 31

5.4.1 Introduction 31

5.4.2 Atorvastatin Calcium Tablets, 40 mg 31

5.4.3 Atorvastatin calcium 10 mg 31

5.4.4 Atorvastatin 32

5.5 Pricing Evolution 32

6 Atorvastatin API Market, by Application

6.1 Introduction 33

6.2 Hypercholesterolemia 35

6.3 Hypertriglyceridemia 36

6.4 Dyslipidemia 37

6.5 Others 38

7 Global Atorvastatin API Market, by Region

7.1 Introduction 39

7.2 North America 42

Atorvastatin API Market, by Application

7.2.1 U.S. 43

Atorvastatin API Market, by Application

7.2.2 Canada 44

Atorvastatin API Market, by Application

7.3 Latin America 45

Atorvastatin API Market, by Application

7.4 Europe 46

Atorvastatin API Market, by Application

7.4.1 Spain 47

Atorvastatin API Market, by Application

7.4.2 France 48

Atorvastatin API Market, by Application

7.4.3 UK 49

Atorvastatin API Market, by Application

7.4.4 Germany 50

Atorvastatin API Market, by Application

7.4.5 Italy 51

Atorvastatin API Market, by Application

7.4.6 Eastern Europe 52

Atorvastatin API Market, by Application

7.4.7 Rest of Europe 53

Atorvastatin API Market, by Application

7.5 Asia-Pacific 54

Atorvastatin API Market, by Application

7.5.1 China 55

Atorvastatin API Market, by Application

7.5.2 India 56

Atorvastatin API Market, by Application

7.5.3 Japan 57

Atorvastatin API Market, by Application

7.5.4 Rest of Asia-Pacific 58

Atorvastatin API Market, by Application

7.6 The Middle East and Africa 59

Atorvastatin API Market, by Application

7.6.1 Middle East 60

Atorvastatin API Market, by Application

7.6.2 Africa 61

Atorvastatin API Market, by Application

8 Competitive Landscape

8.1 Competitive Landscape 63

8.1.1 Introduction 63

8.1.2 Key Development Analysis 64

8.1.3 Market Strategy Analysis 64

9 Company Profiles

9.1 Pfizer Inc 65

9.1.1 Financial Overview 65

9.1.2 Products/Services Offered 66

9.1.3 Key Developments 66

9.1.4 SWOT Analysis 66

9.1.5 Key Strategies 66

9.2 Dr. Reddy’s Laboratories Ltd 67

9.2.1 Financial Overview 67

9.2.2 Products/Services Offered 68

9.2.3 Key Developments 68

9.2.4 SWOT Analysis 68

9.2.5 Key Strategies 68

9.3 Sun Pharmaceutical Industries Ltd 69

9.3.1 Financial Overview 69

9.3.2 Products/Services Offered 70

9.3.3 Key Developments 70

9.3.4 SWOT Analysis 70

9.3.5 Key Strategies 70

9.4 Mylan N.V. 71

9.4.1 Financial Overview 71

9.4.2 Products/Services Offered 72

9.4.3 Key Developments 72

9.4.4 SWOT Analysis 72

9.4.5 Key Strategies 72

9.5 Cipla Inc 73

9.5.1 Financial Overview 73

9.5.2 Products/Services Offered 74

9.5.3 Key Developments 74

9.5.4 SWOT Analysis 75

9.5.5 Key Strategies 75

9.6 Zydus Pharmaceuticals, Inc 76

9.6.1 Financial Overview 76

9.6.2 Products/Services Offered 77

9.6.3 Key Developments 77

9.6.4 SWOT Analysis 77

9.6.5 Key Strategies 77

9.7 Apotex Inc 78

9.7.1 Financial Overview 78

9.7.2 Products/Services Offered 78

9.7.3 Key Developments 78

9.7.4 SWOT Analysis 79

9.7.5 Key Strategies 79

9.8 Akron Pharma Inc. 80

9.8.1 Financial Overview 80

9.8.2 Products/Services Offered 80

9.8.3 Key Developments 80

9.8.4 SWOT Analysis 80

9.8.5 Key Strategies 80

9.9 Accord-UK Ltd 81

9.9.1 Financial Overview 81

9.9.2 Products/Services Offered 81

9.9.3 Key Developments 81

9.9.4 SWOT Analysis 82

9.9.5 Key Strategies 82

9.10 Sanis 83

9.10.1 Financial Overview 83

9.10.2 Products/Services Offered 83

9.10.3 Key Developments 83

9.10.4 SWOT Analysis 84

9.10.5 Key Strategies 84

10 Conclusion

11 List of Tables

TABLE 1 LIST OF ASSUMPTIONS 22

TABLE 2 ATORVASTATIN API MARKET: PIPELINE ANALYSIS 31

TABLE 3 PRICING EVOLUTION (2020–2020), BY REGION (USD PER KG) 32

TABLE 4 GLOBAL ATORVASTATIN API, BY APPLICATION, 2020–2027 (USD MILLION) 33

TABLE 5 GLOBAL ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 34

TABLE 6 GLOBAL ATORVASTATIN API MARKET FOR HYPERCHOLESTEROLEMIA, BY REGION, 2020–2027 (USD MILLION) 35

TABLE 7 GLOBAL ATORVASTATIN API MARKET FOR HYPERCHOLESTEROLEMIA, BY REGION, 2020–2027 (KILO TONS) 35

TABLE 8 GLOBAL ATORVASTATIN APIMARKET FOR HYPERTRIGLYCERIDEMIA, BY REGION, 2020–2027 (USD MILLION) 36

TABLE 9 GLOBAL ATORVASTATIN API MARKET FOR HYPERTRIGLYCERIDEMIA, BY REGION, 2020–2027 (KILO TONS) 36

TABLE 10 GLOBAL ATORVASTATIN API MARKET FOR DYSLIPIDEMIA, BY REGION, 2020–2027 (USD MILLION) 37

TABLE 11 GLOBAL ATORVASTATIN APIMARKET FOR DYSLIPIDEMIA, BY REGION, 2020–2027 (KILO TONS) 37

TABLE 12 GLOBAL ATORVASTATIN API MARKET FOR OTHERS, BY REGION, 2020–2027 (USD MILLION) 38

TABLE 13 GLOBAL ATORVASTATIN API MARKET FOR OTHERS, BY REGION, 2020–2027 (KILO TONS) 38

TABLE 14 GLOBAL ATORVASTATIN API MARKET, BY REGION, 2020–2027 (USD MILLION) 40

TABLE 15 GLOBAL ATORVASTATIN API MARKET, BY REGION, 2020–2027 (KILO TONS) 41

TABLE 16 GLOBAL ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 41

TABLE 17 GLOBAL ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 41

TABLE 18 NORTH AMERICA ATORVASTATIN API MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 42

TABLE 19 NORTH AMERICA ATORVASTATIN APIMARKET, BY COUNTRY, 2020–2027 (KILO TONS) 42

TABLE 20 NORTH AMERICA ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 42

TABLE 21 NORTH AMERICA ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 43

TABLE 22 U.S. ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 43

TABLE 23 U.S. ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (KILO TONS) 44

TABLE 24 CANADA ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (USD MILLION) 44

TABLE 25 CANADA ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (KILO TONS) 44

TABLE 26 LATIN AMERICA ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 45

TABLE 27 LATIN AMERICA ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 45

TABLE 28 EUROPE ATORVASTATIN API MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 46

TABLE 29 EUROPE ATORVASTATIN API MARKET, BY COUNTRY, 2020–2027 (KILO TONS) 46

TABLE 30 EUROPE ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 47

TABLE 31 EUROPE ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 47

TABLE 32 SPAIN ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 47

TABLE 33 SPAIN ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 48

TABLE 34 FRANCE ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 48

TABLE 35 FRANCE ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 49

TABLE 36 UK ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (USD MILLION) 49

TABLE 37 UK ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (KILO TONS) 49

TABLE 38 GERMANY ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 50

TABLE 39 GERMANY ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 50

TABLE 40 ITALY ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 51

TABLE 41 ITALY ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 51

TABLE 42 EASTERN EUROPE ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 52

TABLE 43 EASTERN EUROPE ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 52

TABLE 44 REST OF EUROPE ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 53

TABLE 45 REST OF EUROPE ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 53

TABLE 46 ASIA-PACIFIC ATORVASTATIN API MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 54

TABLE 47 ASIA-PACIFIC ATORVASTATIN API MARKET, BY COUNTRY, 2020–2027 (KILO TONS) 54

TABLE 48 ASIA-PACIFIC ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 54

TABLE 49 ASIA-PACIFIC ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 55

TABLE 50 CHINA ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 55

TABLE 51 CHINA ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (KILO TONS) 56

TABLE 52 INDIA ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 56

TABLE 53 INDIA ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 56

TABLE 54 JAPAN ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 57

TABLE 55 JAPAN ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (KILO TONS) 57

TABLE 56 REST OF ASIA-PACIFIC ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 58

TABLE 57 REST OF ASIA-PACIFIC ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 58

TABLE 58 THE MIDDLE EAST AND AFRICA ATORVASTATIN API MARKET, BY REGION, 2020–2027 (USD MILLION) 59

TABLE 59 THE MIDDLE EAST AND AFRICA ATORVASTATIN API MARKET, BY REGION, 2020–2027 (KILO TONS) 59

TABLE 60 THE MIDDLE EAST AND AFRICA ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 59

TABLE 61 THE MIDDLE EAST AND AFRICA ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (KILO TONS) 60

TABLE 62 MIDDLE EAST ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 60

TABLE 63 MIDDLE EAST ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 61

TABLE 64 AFRICA ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (USD MILLION) 61

TABLE 65 AFRICA ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (KILO TONS) 62

12 List of Figures

FIGURE 1 MARKET SYNOPSIS 13

FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL ATORVASTATIN API MARKET 14

FIGURE 3 GLOBAL ATORVASTATIN API MARKET ANALYSIS, BY APPLICATION 15

FIGURE 4 GLOBAL ATORVASTATIN API MARKET ANALYSIS BY REGION 16

FIGURE 5 GLOBAL ATORVASTATIN API MARKET: MARKET STRUCTURE 17

FIGURE 6 RESEARCH PROCESS OF MRFR 18

FIGURE 7 TOP-DOWN & BOTTOM-UP APPROACH 21

FIGURE 8 MARKET DYNAMICS OVERVIEW 23

FIGURE 9 DRIVERS IMPACT ANALYSIS 24

FIGURE 10 RESTRAINTS IMPACT ANALYSIS 25

FIGURE 11 SUPPLY CHAIN: GLOBAL ATORVASTATIN API MARKET 27

FIGURE 12 PORTER'S FIVE FORCES ANALYSIS OF THE GLOBAL ATORVASTATIN API MARKET 28

FIGURE 13 GLOBAL ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 33

FIGURE 14 GLOBAL ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 34

FIGURE 15 GLOBAL ATORVASTATIN API MARKET BY REGION, 2020 (VALUE %) 39

FIGURE 16 GLOBAL ATORVASTATIN API MARKET BY REGION, 2020–2027 (KILO TONS) 40

Atorvastatin API Market Speak to Analyst Request a Free Sample

Atorvastatin API Market Overview


The Atorvastatin API Market Size register at a CAGR of 4.18% to reach USD 490.52Million by the estimated period of 2023. 


Atorvastatin API Market has been basically benefitted by the mounting implementation and execution of atorvastatin in dealing with cardiovascular infections. The ascent of dyslipidemia in China conveys opportunities for development in this market. Restricting prosperity impacts identified with atorvastatin is expected to keep the market development and its chart. An assumption for driving the Atorvastatin API Market and its development has been seen to lead after the reception of atorvastatin in the treatment of cardiovascular sicknesses. 


A high volume of kidney issues, joined with high measurement of the medication in the older people to control their cholesterol levels, can look good for the Atorvastatin API Market. Endorsement of large-scale manufacturing of medications from government offices can drive the atorvastatin API industry development. As of late, the U.S. FDA allowed a permit to Morepen Laboratories for the creation of atorvastatin calcium for fare to the U.S. Severe guideline laid out by government organizations just as consistence for changing to green techniques for creation can look good for the Atorvastatin API Market Share. In any case, unfavorable impacts of the medication can hamper the Atorvastatin API Market development. 


North America represented the biggest portion of the overall industry of 40.64% in 2017, and the local market is projected to enroll a CAGR of 3.10% during the estimated time frame. Asia-Pacific is required to enlist the quickest CAGR. The Chinese Atorvastatin API Industryt is projected to show the most elevated development pace of 5.86% during the figure time frame from 2018 to 2023. Based on application, type, and region, the global market is segmented to provide a detailed view of the Atorvastatin API Industry position and development. Atorvastatin API Market Outlook offers a detailed analysis of the market, including drivers, opportunities, challenges, restraints, and growth in the Atorvastatin API Industry. With the help of this analysis, you could get a better analysis of the market position and its expected growth during the estimated time frame. 


COVID 19 Analyses


The Covid outbreak and spreading have begun to hit a large area of the country by raising the costs of key fixings. Presently the costs for nutrients and penicillin are twofold the cost. The cost of paracetamol has gone up. Another significant effect is that a drug organization faces disturbances because of broadened processing plant terminations. In the event that the pandemic precedes, reserves of drugs, crude drug materials, and different synthetics may diminish, bringing about deficiencies. The Atorvastatin API Market is expected to enhance its growth in the future estimated period. 


Atorvastatin API Global Market Revenue, by Application, 2023 (USD Thousand)  Atorvastatin API Market_Image


Sources: MRFR Analysis


Market Dynamics



  • Major Drivers of the Market



High pervasiveness of cardiovascular sicknesses is required to be the essential driver of the Atorvastatin API Market during the estimated time frame. Rising instances of dyslipidemia in China can open up new roads of development for the Atorvastatin API Market. High fatty oil levels and LDL cholesterol brought about by corpulence and inactive ways of life of patients can loan some assistance to the atorvastatin API industry. 

A high volume of kidney problems, joined with high measurements of the medication in the older people to control their cholesterol levels, can look good for the Atorvastatin API Market Growth. Endorsement of large-scale manufacturing of medications from government offices can drive the atorvastatin API industry development.



  • Significant Opportunities For The Market



The players working in the Global Atorvastatin API Market are focused on product dispatch, alongside growing their worldwide impressions by entering undiscovered business sectors. The Product dispatch is considered as a significant opportunity for the Atorvastatin API Market development. This opportunity is opening doors for the key players to enhance the market growth to a great extent. 



  • Market Restraints



Importing crude materials is confined, which will influence the assembling action and thus prompt lower deals and restrain the Atorvastatin API Market Growth. Deficient auxiliary supplies like jugs, covers, and bundling material for medication will influence the yield, the effect of which is required to be felt over a time of the next three to four quarters. This stockpile deficiency may likewise prompt evaluating instability in the future period. Organizations will attempt to keep up with inventories for a longer term, and the cushion limit will be expanded, which may influence the stock cycles.



  • Cumulative Growth Analysis



A high volume of kidney problems joined with a high dose of the medication in the older people to control their cholesterol levels can look good for the Atorvastatin API Market. Endorsement of large-scale manufacturing of medications from government organizations can drive the atorvastatin API industry development. As of late, the U.S. FDA conceded a permit to Morepen Laboratories for the creation of atorvastatin calcium for fare to the U.S. Severe guideline laid out by government organizations just as consistence for changing to green techniques for creation can look good for the Atorvastatin API Industry development for the estimated future period. In any case, the unfriendly impacts of the medication can hamper the market development.

Atorvastatin API Global Market Share, by Region, 2017 (%)  Atorvastatin API Market_Image                     


Sources: MRFR Analysis


Segment Overview



  • Based on Application


Based on application, the Atorvastatin API industry is segmentation into Hypercholesterolemia, Hypertriglyceridemia, and Dyslipidemia. Others are incorporated. Before the year's over 2023, the hypercholesterolemia portion is probably going to make preparations and record an extensive CAGR to arrive at USD 2,10,753.23 thousand. The players working in the  Atorvastatin API industry are focusing on mounting their worldwide presence by entering immaculate business sectors alongside some item dispatches and choices likely. Rather it is normal that a tall event of hypercholesterolemia is required to shoot up the Atorvastatin API Market development. 



  • Based on Region


On the basis of region, the worldwide Atorvastatin API Market is divided and designated into a worldwide regions like North America, Asia-Pacific, Middle East, and Africa, Latin America, and the Chinese market. Regularly, by Region, the Atorvastatin API Market is fragmented into the US, Canada, Latin America. The European locale is additionally covered right from Germany, UK, France, Spain, Italy, Eastern Europe, and the Rest of Europe. The Asian Pacific reach covers the nations like China, India, Japan, and the remainder of Asia Pacific. It additionally covers the Middle East and Africa.


Regional Analysis


The regional analysis of the atorvastatin API industry includes areas like Europe, North America, Asia Pacific, the Middle East, and Africa. The North American district was responsible for the biggest market part of 40.64% in 2017, and the provincial market is relied upon to record a CAGR of 3.10 % through the conjecture time frame. Additionally, the Asia Pacific is projected to use the quickest CAGR. The local Chinese market is projected to show the greatest improvement pace of 5.86 % during the conjecture time frame from 2018 to 2023. The European local market is evaluated to outperform USD 1, 31,094.04 thousand constantly 2023. The high pervasiveness of blended dyslipidemia and hypercholesterolemia are prompting the development of the Atorvastatin API industry in the district. France is the critical provider to the advancement of the local market, trailed by the UK.


Competitive Landscape


The major Atorvastatin API Market Players are mentioned below: 



  • Teva Pharmaceutical Industries Ltd (Israel)

  • Sun Pharmaceutical Industries Ltd (India)

  • Centrient Pharmaceuticals (The Netherlands) 

  • Morepen Laboratories Ltd (India)

  • Dr. Reddy’s Laboratories Ltd (India)

  • Anuh Pharma Ltd (India)

  • Jubilant Life Sciences Ltd (India)

  • Ind-Swift Labs Ltd (India)

  • Zhejiang Hisun Pharmaceutical Co Ltd (China)

  • Cadila Pharmaceuticals (India)


Recent Developments



  • Nov 2018 Zydus Cadila, a notable Drug creator, has reported that it has gotten endorsement from the US wellbeing controller to advance Atorvastatin Calcium tablets, a cholesterol-bringing down drug. 

  • The gathering based out of Ahmedabad has gotten the last underwriting from the US Food and Drug Administration (USFDA) to sell the medication in the groupings of 10 mg, 20 mg, 40 mg, and 80 mg individually.


Report Overview


The Atorvastatin API Market Analysis or overview is as follows:



  • Market Overview

  • COVID 19 Analysis

  • Market Dynamics

  • Market Segment Overview

  • Regional Analysis as per the Market Forecast. 

  • Market Competitive Landscape

  • Market Trends Developments


This report has a clear focus upon highlighting the growth aspects of the global Market Value. Along with that, this report also intends to put up the competitive landscape and recent developments on the table to explain the position of this global Market.



Report Scope:
Report Attribute/Metric Details
  Market Size   2023: USD 490.52Million
  CAGR   2017-2023: 4.18%
  Base Year   2019
  Forecast Period   2023
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Application And Region
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Teva Pharmaceutical Industries Ltd (Israel), Jubilant Life Sciences Ltd (India), Dr. Reddy’s Laboratories Ltd (India), Sun Pharmaceutical Industries Ltd (India), Ind-Swift Labs Ltd (India), Morepen Laboratories Ltd (India), Zhejiang Hisun Pharmaceutical Co Ltd (China), Anuh Pharma Ltd (India), Centrient Pharmaceuticals (The Netherlands) and Cadila Pharmaceuticals (India)
  Key Market Opportunities   Product launches
  Key Market Drivers   High adoption of atorvastatin for the treatment of cardiovascular diseases


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

atorvastatin API 425 million by 2023.

Atorvastatin API Market is expected to exhibit a strong 3.34% CAGR over the forecast period.

Atorvastatin is mainly used to lower LDL levels in the blood, thus averting major cardiovascular incidents.

High adoption of atorvastatin for the treatment of cardiovascular diseases is the major driver for the market.

North America dominated the global market in 2017 with a share of more than 40%.